NCT06712654 - A Study to Evaluate Safety, Tolerability and Efficacy of AP306 At Fixed Doses in Patients with Hyperphosphatemia | Biotech Hunter

Enrollment

144

Participants

Timeline

Start Date

April 10, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

December 30, 2025

Conditions

HyperphosphatemiaChronic Kidney Disease Requiring Hemodialysis

Interventions

DRUG

AP306 75mg TID

receiving orally AP306 75mg (one tablet), three times a day

DRUG

AP306 100mg TID

receiving orally AP306 100 mg (one tablet), three times a day.

DRUG

AP306 125mg TID

receiving orally AP306 125 mg (one tablet), three times a day

DRUG

AP306 125mg BID

receiving orally AP306 125 mg (one tablet), three times a day, among which one is a placebo tablet

DRUG

AP306 150mg BID

receiving orally AP306 150 mg (one tablet), three times a day, among which one is a placebo tablet

DRUG

Placebo TID

receiving orally one placebo tablet of AP306, three times a day